Dentsply Sirona Lowers 2026 EPS Outlook After Third-Quarter Sales Slide
Dentsply Sirona (XRAY) lowered its 2026 adjusted EPS outlook to $1.20-$1.30 after Q3 sales fell 7.6% to $836M and adjusted EPS dropped 29.4% to $0.29. The company expects $3.5B in 2026 sales, down from its prior $3.5B-$3.6B forecast. Q3 net loss was $2M, improved from a $427M loss in Q3 2025. Sales varied across business segments, with Wellspect Healthcare up 10.1%.
How this was made

The 30-second read
Why it matters
The guidance reduction is the primary market‑moving event; analysts will likely downgrade forecasts, and investors may trim exposure.
Market read
First‑time disclosure of a lower EPS outlook for a mid‑cap dental equipment maker, creating immediate downside risk.
What to watch
One‑time tariff refund benefit excluded; underlying demand trends may improve later in the year.
Background
Dentsply Sirona reported Q3 results with sales down 7.6% YoY and a GAAP net loss, prompting a revision of its 2026 EPS outlook.
Market effects
Dental equipment sector may see broader valuation pressure as peers face similar demand slowdown.
U.S. healthcare equipment stocks could see modest pullback.
Limited to companies with exposure to dental product markets.
Counterpoint
If the company can accelerate its Return‑to‑Growth plan, the cut may be temporary and present a buying opportunity.
Key entities
- ExecutiveDan Scavilla
President and CEO of Dentsply Sirona who commented on the Return‑to‑Growth Action Plan.




